IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola

The department investigates Ulcerative Colitis as part of its focus on digestive system diseases. The study seeks to determine whether a new medication can achieve clinical remission more effectively than placebo. Research is carried out at IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola.

• Clinical remission assessment
• Placebo-controlled design
• Monotherapy evaluation

Two investigators lead this effort, aiming to bring innovative treatment options to patients.

The team studies Crohn’s Disease within the broader field of digestive health. The objective is to evaluate a combined therapy that may improve remission rates while also addressing weight concerns. The work is performed at IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola.

• Combination therapy evaluation
• Weight management outcomes
• Endoscopic remission tracking

A pair of investigators oversee the trial, exploring synergistic drug effects for better patient outcomes.

Researchers address Obesity or Overweight as a comorbidity in digestive disease patients. The trial aims to assess whether adding a novel agent to standard care can enhance weight loss alongside disease remission. All activities take place at IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola.

• Weight reduction outcomes
• Metabolic impact analysis
• Synergistic drug effects

Two dedicated investigators are guiding the study to improve therapeutic strategies for patients with overlapping digestive and metabolic conditions.